Hormone Replacement Therapy in Patient with Gynecological Malignancies
DOI:
https://doi.org/10.31584/psumj.2023261054Keywords:
cervical cancer, endometrial cancer, gynecologic cancer, ovarian cancer, postmenopausal symptom, vaginal cancer, vulvar cancerAbstract
Gynecological cancer patients having undergone surgery, chemotherapy or radiation can suffer some effects; particularly in pre-menopausal patients. Postmenopausal symptoms; such as hot flushes and genitourinary syndromes, may occur faster and be more severe than in pre-menopausal patients. In these patients, Hormone replacement therapy (HRT), should be access for severity of symptoms, stage, residual of lesion after treatment, risk of recurrent of disease and type of cancer. HRT should be offered for patients with low risk of recurrent of disease; such as, stage I-II, and estrogen-independent tumors; such as vulvar cancer, vaginal cancer and cervical cancer. However, HRT should be cautioned in estrogen-dependent tumors; such as endometrial cancer and ovarian cancer; especially, endometrioid type and granulosa cell tumors. This is due to there being presence of responses to ant-estrogen therapies; such as low-grade serous of ovarian cancer and granulosa cell tumors in addition to increased risk of venous thromboembolic events; including clear cells carcinoma of ovarian cancer.
References
International Agency for Research on Cancer. GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020 [homepage on the Internet]. International Agency for Research on Cancer. 2022 [cited 2022 Jun 1]. Available from: https://gco.iarc.fr/today/home.
Rojanamatin J, Ukranun W, Supaattagorn P, Chiawiriyabunya I, Wongsena M, Chaiwerawattana A, et al. Cancer in Thailand Vol.X, 2016-2018. Bangkok: National Cancer Institute; 2021.
Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms after cancer. Climacteric 2019;22:572-8.
Brennan A, Hickey M. The use of menopausal hormone therapy after cancer. Best Pract Res Clin Obstet Gynaecol 2022;81:22-30.
Garg N, Behbehani S, Kosiorek H, Wasson M. Hormone replacement therapy prescription after premature surgical menopause. J Minim Invasive Gynecol 2020;27:1618-23.
Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, et al. The 2020 menopausal hormone therapy guidelines. J Menopausal Med 2020;26:69-98.
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975-4011.
Col NF FK, Ewan-Whyte C, Miller H. In the clinic. Menopause. Ann Intern Med 2009;7:ITC4-1-15.
Pillay OC, Manyonda I. The surgical menopause. Best Pract Res Clin Obstet Gynaecol 2022;81:111-8.
Lumsden MA. The NICE Guideline - Menopause: diagnosis and management. Climacteric 2016;19:426-9.
The Australasian Menopause Society. Surgical menopause 2018 Available from: https://www.menopause.org.au/hp/information-sheets/surgical-menopause.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:Cd004143.
Hua H, Zhang H, Kong Q, Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol 2018;7:24.
Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol Oncol Res 2020;26:63-78.
Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol 2015;54:R31-53.
Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol Oncol 2004;92:827-32.
Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65:190-7.
Brennan A, Brennan D, Rees M, Hickey M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int J Gynecol Cancer 2021;31:352-9.
Saeaib N, Sriplung H, Pichatechaiyoot A, Bilheem S. Trends in incidence of uterine cancer in Songkhla, Southern Thailand. J Gynecol Oncol 2019;30:e22.
Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-30.
Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-91.
Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-200.
Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555-60.
Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006;16:805-8.
Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A gynecologic oncology group study. J Clin Oncol 2006;24:587-92.
Cho HW, Ouh YT, Lee JK, Hong JH. Effects of hormone therapy on recurrence in endometrial cancer survivors: A nationwide study using the Korean health insurance review and assessment service database. J Gynecol Oncol 2019;30:e51.
Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014;50:1628-37.
Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018;5:Cd008830.
Londero AP, Parisi N, Tassi A, Bertozzi S, Cagnacci A. Hormone replacement therapy in endometrial cancer survivors: A meta-analysis. J Clin Med 2021;10.
ACOG committee opinion: Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 2001;73:77-9.
Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the institut national du cancer and the société française d’oncologie gynécologique. Int J Gynecol Cancer 2011;21:945-50.
Ebina Y, Katabuchi H, Mikami M, Nagase S, Yaegashi N, Udagawa Y, et al. Japan society of gynecologic oncology guidelines 2013 for the treatment of uterine body neoplasms. Int J Clin Oncol 2016;21:419-34.
Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol 2020;157:303-6.
Rees M, Angioli R, Coleman RL, Glasspool R, Plotti F, Simoncini T, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas 2020;134:56-61.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Uterine neoplasm [homepage on Internet]. 2022 [cited 2022 May 26]. Available from: NCCN.org.
Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2018;143:59-78.
Zamani N, Rezaei Poor M, Ghasemian Dizajmehr S, Alizadeh S, Modares Gilani M. Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences. BMC Womens Health 2021;21:282.
Liu Y, Ma L, Yang X, Bie J, Li D, Sun C, et al. Menopausal hormone replacement therapy and the risk of ovarian cancer: A meta-analysis. Front Endocrinol (Lausanne) 2019;10:801.
Eeles RA, Tan S, Wiltshaw E, Fryatt I, A’Hern RP, Shepherd JH, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-62.
Bebar S, Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 2000;21:192-6.
Ursic-Vrsaj M, Md P, Bebar S, Zakelj M, Primic Md P. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001;8:70-5.
Wen Y, Huang H, Huang H, Wu M, Shen K, Pan L. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric 2013;16:673-81.
Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R, et al. Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstet Gynecol 2016;127:837-47.
Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017;35:1103-11.
Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006;119:2907-15.
Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999;86:1013-8.
Li L, Pan Z, Gao K, Zhang W, Luo Y, Yao Z, et al. Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncol Lett 2012;3:244-9.
Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the aht randomized trial. J Clin Oncol 2015;33:4138-44.
Li D, Ding C-Y, Qiu L-H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2015;139:355-62.
Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause 2016;23:335-42.
Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev 2020;1:Cd012559.
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer. Bull Cancer 2018;105:299-314.
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018;143:22-36.
Sriplung H, Singkham P, Iamsirithaworn S, Jiraphongsa C, Bilheem S. Success of a cervical cancer screening program: trends in incidence in songkhla, southern Thailand, 1989-2010, and prediction of future incidences to 2030. Asian Pac J Cancer Prev 2014;15:10003-8.
Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res 2010;30:1341-5.
Vargiu V, Amar ID, Rosati A, Dinoi G, Turco LC, Capozzi VA, et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric 2021;24:120-7.
Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169-77.
Richardson A, Watson L, Persic M, Phillips A. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post reproductive health 2021;27:167-73.
Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. Int J Gynaecol Obstet 2021;155:7-18.
Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet 2021;155:19-27.
Laitman CJ. DES exposure and the aging woman: mothers and daughters. Current women’s health reports 2002;2:390-3.
Harris RM, Waring RH. Diethylstilboestrol--a long-term legacy. Maturitas 2012;72:108-12.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Author and Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
